LSE:AZNPharmaceuticals
AstraZeneca’s NYSE Debut Pairs With Major Obesity And China Expansion
AstraZeneca (LSE:AZN) has begun trading its ordinary shares on the New York Stock Exchange, expanding access for US investors.
The company announced an $18.5b weight loss drug partnership with CSPC Pharmaceuticals focused on obesity and diabetes treatments.
AstraZeneca also unveiled a $15b investment plan in China to expand manufacturing and R&D, including cell therapy and radioconjugates.
AstraZeneca, best known for its broad pharmaceutical portfolio across oncology, cardiovascular,...